Last $0.22 USD
Change Today -0.015 / -6.38%
Volume 45.6K
GOVX On Other Exchanges
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

geovax labs inc (GOVX) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/11/13 - $0.97
52 Week Low
07/11/14 - $0.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GEOVAX LABS INC (GOVX)

Related News

No related news articles were found.

geovax labs inc (GOVX) Related Businessweek News

No Related Businessweek News Found

geovax labs inc (GOVX) Details

GeoVax Labs, Inc. operates as a biotechnology company. The company’s develops vaccines that prevent and fight human immunodeficiency virus (HIV) infections that result in acquired immunodeficiency syndrome (AIDS). Its vaccines incorporate two delivery components, including a recombinant DNA and recombinant poxvirus, known as modified vaccinia Ankara, which deliver genes that encode inactivated HIV derived proteins to the immune system. The company’s vaccines under development addressing the clade B subtype of the HIV virus includes GOVX-B11 and GOVX-B21 vaccines that are n Phase I clinical trials to prevent HIV infection, and to serve as a therapy for individuals who are already infected with HIV. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.

6 Employees
Last Reported Date: 03/27/14
Founded in 2001

geovax labs inc (GOVX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $275.0K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $225.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $212.6K
Compensation as of Fiscal Year 2013.

geovax labs inc (GOVX) Key Developments

GeoVax Labs, Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Corporate Update on HIV Immunotherapy Program

GeoVax Labs, Inc. announced consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported grant revenue of $180,000 against $442,000 a year ago. Net loss was $680,000 against $526,000 a year ago. Loss per common share was $0.03 against $0.02 a year ago. For the six months, the company reported grant revenue of $338,000 against $1,239,000 a year ago. Net loss was $1,295,000 against $1,223,000 a year ago. Loss per common share was $0.05 against $0.06 a year ago. The company provided clinical development update on HIV Immunotherapy Program. The company recently completed the first Phase 1 trial (GV-TH-01) investigating the therapeutic potential of its DNA/MVA vaccine regimen (GOVX-B11) in HIV-infected patients. GOVX-B11 was tested for safety and immunogenicity in nine HIV-infected patients who were on antiretroviral drug therapy (ART). After completing the inoculation series, patients suspended ART for a 12-week period and were observed for their ability to control virus re-emergence in the absence of drugs. ART was re-instituted after 12 weeks, and trial participants were observed for an additional 6 months. Strong safety data results were observed throughout the trial. GeoVax’s analysis of the trial data indicates that, during the vaccination phase of the trial, evidence of the beneficial effect of vaccine was measured by enhanced CD8+ T cells elicited in 8 of 9 participants and enhanced CD4+ T cells in 5 of 9 participants. Antibody responses were boosted in 4 of 9 participants. Analyses during the treatment interruption phase suggested that individuals with the best immune responses to the vaccine had lower levels of re-emergent virus. The company expects to formally publish the full study results for GV-TH-01 in a scientific journal in late 2014. Although the GV-TH-01 results were not suggestive of a significant clinical benefit of GOVX-B11 alone, the immune response data from the trial have given company a foundation for proceeding with the development of an immunotherapy program as part of the National Institutes of Health (NIH) ‘cure agenda’. The company is currently developing a protocol for a Phase 1/2 clinical trial using a proprietary agent to induce latently infected cells to produce virus (shock) while the infected patient remains on ART. Successful re-activation of viral reservoirs is the first step towards a ‘shock and kill’ approach to reducing viral reservoirs.

GeoVax Labs, Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-09-2014 03:20 PM

GeoVax Labs, Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-09-2014 03:20 PM. Venue: New York Palace Hotel – 455 Madison Avenue, New York, NY 10022, United States. Speakers: Robert T. McNally, Chief Executive Officer, President and Director.

GeoVax Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2014

GeoVax Labs, Inc. reported earnings results for the first quarter ended March 31, 2014. The company reported a net loss for the three months ended March 31, 2014 was $614,918, or $0.02 per share. For the three months ended March 31, 2013, the company reported a loss of $696,797, or $0.03 per share, based on 20.2 million weighted average shares outstanding. Grant revenue was $157 against $797 a year ago. Loss from operations was $617 against $698 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GOVX:US $0.22 USD -0.015

GOVX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,601 JPY +17.00
Bavarian Nordic A/S kr113.00 DKK +0.50
CSL Ltd A$72.94 AUD +0.33
Emergent Biosolutions Inc $21.80 USD -0.40
Solvay SA €122.60 EUR 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation GOVX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.9x
Price/Book 17.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GEOVAX LABS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at